Document is current
Any future updates will be listed below
-
Authors
Jiang, Dadi https://orcid.org/0000-0002-0935-3908
Guo, Youming
Wang, Tianyu
Wang, Liang https://orcid.org/0000-0001-5038-694X
Yan, Yuelong https://orcid.org/0000-0001-8495-6445
Xia, Ling
Bam, Rakesh https://orcid.org/0000-0003-4067-3798
Yang, Zhifen
Lee, Hyemin https://orcid.org/0000-0002-7387-5452
Iwawaki, Takao
Gan, Boyi https://orcid.org/0000-0001-8884-6040
Koong, Albert C. https://orcid.org/0000-0001-9824-1643
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP190192, RP230072, RP190192)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA274220, U54CA274220, R01CA181196, R01CA244144, R01CA247992, R01CA269646, U54CA274220)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The Olga Keith and Harry Carothers Wiess Distinguished University Chair in Cancer Research Endowment Fund
- License Information
-
More Information
Article History
Received: 30 September 2022
Accepted: 26 April 2024
First Online: 15 May 2024
Competing interests
: B.G. is an inventor with patent applications involving targeting ferroptosis in cancer therapy (patent no. PCT/US2022/018663). A.C.K. is a stockholder in Aravive, Inc. The remaining authors declare no competing interests.
